1. Neuroscience

Concurrent decoding of distinct neurophysiological fingerprints of tremor and bradykinesia in Parkinson's disease

  1. Peter M Lauro  Is a corresponding author
  2. Shane Lee
  3. Daniel E Amaya
  4. David D Liu
  5. Umer Akbar
  6. Wael F Asaad  Is a corresponding author
  1. Brown University, United States
  2. Brigham and Women's Hospital, United States
https://doi.org/10.7554/eLife.84135
Share this article
Cite this article
  1. Peter M Lauro
  2. Shane Lee
  3. Daniel E Amaya
  4. David D Liu
  5. Umer Akbar
  6. Wael F Asaad
(2023)
Concurrent decoding of distinct neurophysiological fingerprints of tremor and bradykinesia in Parkinson's disease
eLife 12:e84135.
https://doi.org/10.7554/eLife.84135
  2. Download BibTeX
  3. Download .RIS

Abstract

Parkinson's Disease (PD) is characterized by distinct motor phenomena that are expressed asynchronously. Understanding the neurophysiological correlates of these motor states could facilitate monitoring of disease progression and allow improved assessments of therapeutic efficacy, as well as enable optimal closed-loop neuromodulation. We examined neural activity in the basal ganglia and cortex of 31 subjects with PD during a quantitative motor task to decode tremor and bradykinesia - two cardinal motor signs of PD - and relatively asymptomatic periods of behavior. Support-vector regression analysis of microelectrode and electrocorticography recordings revealed that tremor and bradykinesia had nearly opposite neural signatures, while effective motor control displayed unique, differentiating features. The neurophysiological signatures of these motor states depended on the signal type and location. Cortical decoding generally outperformed subcortical decoding. Within the subthalamic nucleus (STN), tremor and bradykinesia were better decoded from distinct subregions. These results demonstrate how to leverage neurophysiology to more precisely treat PD.

Data availability

The raw datasets supporting the current study contain patient information and are unique datasets under continued investigation for additional projects, including those of junior trainees.Deidentified neural/behavioral estimates and related code to reproduce all analyses in the manuscript will be made available in a public repository (Dryad; https://doi.org/10.5061/dryad.h9w0vt4n4).To request raw datasets, please contact the corresponding authors (me@peterlauro.me, wael_asaad@brown.edu) with a project proposal. Based upon the granularity of the data requested and potential for patient information exposure, data sharing would granted in consultation with the Lifespan IRB. There are no commercial restrictions for these data currently.

The following data sets were generated

Article and author information

Author details

  1. Peter M Lauro

    Department of Neuroscience, Brown University, Providence, United States
    For correspondence
    me@peterlauro.me
    Competing interests
    Peter M Lauro, The authors have patents and patent applications (US patent #: 17312155, 17470710) broadly relevant to Parkinson's disease (but not directly based upon this work)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8569-6427

  2. Shane Lee

    Department of Neuroscience, Brown University, Providence, United States
    Competing interests
    Shane Lee, The authors have patents and patent applications (US patent #: 17312155, 17470710) broadly relevant to Parkinson's disease (but not directly based upon this work)..

  3. Daniel E Amaya

    Department of Neuroscience, Brown University, Providence, United States
    Competing interests
    Daniel E Amaya, The authors have patents and patent applications (US patent #: 17312155, 17470710) broadly relevant to Parkinson's disease (but not directly based upon this work)..

  4. David D Liu

    Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States
    Competing interests
    David D Liu, The authors have patents and patent applications (US patent #: 17312155, 17470710) broadly relevant to Parkinson's disease (but not directly based upon this work)..

  5. Umer Akbar

    Robert J and Nancy D Carney Institute for Brain Science, Brown University, Providence, United States
    Competing interests
    Umer Akbar, The authors have patents and patent applications (US patent #: 17312155, 17470710) broadly relevant to Parkinson's disease (but not directly based upon this work)..

  6. Wael F Asaad

    Department of Neuroscience, Brown University, Providence, United States
    For correspondence
    Wael_Asaad@brown.edu
    Competing interests
    Wael F Asaad, The authors have patents and patent applications (US patent #: 17312155, 17470710) broadly relevant to Parkinson's disease (but not directly based upon this work). WFA has received proprietary equipment and technical support for unrelated research through the Medtronic external research program..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4406-9096

Funding

National Institute of Neurological Disorders and Stroke (T32MH020068)

  • Peter M Lauro

Doris Duke Charitable Foundation (Clinical Scientist Development Award#2014101)

  • Wael F Asaad

National Institute of General Medical Sciences (P20 GM103645)

  • Wael F Asaad

Neurosurgery Research and Education Foundation

  • Wael F Asaad

Lifespan Norman Prince Neurosciences Institute

  • Shane Lee
  • Umer Akbar
  • Wael F Asaad

Brown University Robert J. and Nancy D. Carney Institute for Brain Science

  • Peter M Lauro
  • Shane Lee
  • Daniel E Amaya
  • Umer Akbar
  • Wael F Asaad

NIH Office of the Director (S10OD025181)

  • Wael F Asaad

Medtronic

  • Wael F Asaad

WFA has received proprietary equipment and technical support for unrelated research through the Medtronic external research program.The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Patients and control subjects agreeing to participate in this study signed informed consent, and experimental procedures were undertaken in accordance with an approved Rhode Island Hospital human research protocol (Lifespan IRB protocol #263157) and the Declaration of Helsinki.

Copyright

© 2023, Lauro et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 735
    views
  • 118
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Peter M Lauro
  2. Shane Lee
  3. Daniel E Amaya
  4. David D Liu
  5. Umer Akbar
  6. Wael F Asaad
(2023)
Concurrent decoding of distinct neurophysiological fingerprints of tremor and bradykinesia in Parkinson's disease
eLife 12:e84135.
https://doi.org/10.7554/eLife.84135

Share this article

https://doi.org/10.7554/eLife.84135

Categories and tags

Research organism

Further reading

    1. Medicine
    2. Neuroscience

    Blood metabolomic profiling reveals new targets in the management of psychological symptoms associated with severe alcohol use disorder

    Sophie Leclercq, Hany Ahmed ... Nathalie Delzenne
    Research Article

    Background:

    Alcohol use disorder (AUD) is a global health problem with limited therapeutic options. The biochemical mechanisms that lead to this disorder are not yet fully understood, and in this respect, metabolomics represents a promising approach to decipher metabolic events related to AUD. The plasma metabolome contains a plethora of bioactive molecules that reflects the functional changes in host metabolism but also the impact of the gut microbiome and nutritional habits.

    Methods:

    In this study, we investigated the impact of severe AUD (sAUD), and of a 3-week period of alcohol abstinence, on the blood metabolome (non-targeted LC-MS metabolomics analysis) in 96 sAUD patients hospitalized for alcohol withdrawal.

    Results:

    We found that the plasma levels of different lipids ((lyso)phosphatidylcholines, long-chain fatty acids), short-chain fatty acids (i.e. 3-hydroxyvaleric acid) and bile acids were altered in sAUD patients. In addition, several microbial metabolites, including indole-3-propionic acid, p-cresol sulfate, hippuric acid, pyrocatechol sulfate, and metabolites belonging to xanthine class (paraxanthine, theobromine and theophylline) were sensitive to alcohol exposure and alcohol withdrawal. 3-Hydroxyvaleric acid, caffeine metabolites (theobromine, paraxanthine, and theophylline) and microbial metabolites (hippuric acid and pyrocatechol sulfate) were correlated with anxiety, depression and alcohol craving. Metabolomics analysis in postmortem samples of frontal cortex and cerebrospinal fluid of those consuming a high level of alcohol revealed that those metabolites can be found also in brain tissue.

    Conclusions:

    Our data allow the identification of neuroactive metabolites, from interactions between food components and microbiota, which may represent new targets arising in the management of neuropsychiatric diseases such as sAUD.

    Funding:

    Gut2Behave project was initiated from ERA-NET NEURON network (Joint Transnational Call 2019) and was financed by Academy of Finland, French National Research Agency (ANR-19-NEUR-0003-03) and the Fonds de la Recherche Scientifique (FRS-FNRS; PINT-MULTI R.8013.19, Belgium). Metabolomics analysis of the TSDS samples was supported by grant from the Finnish Foundation for Alcohol Studies.

    1. Neuroscience

    A deep learning approach for automated scoring of the Rey–Osterrieth complex figure

    Nicolas Langer, Maurice Weber ... Ce Zhang
    Tools and Resources

    Memory deficits are a hallmark of many different neurological and psychiatric conditions. The Rey–Osterrieth complex figure (ROCF) is the state-of-the-art assessment tool for neuropsychologists across the globe to assess the degree of non-verbal visual memory deterioration. To obtain a score, a trained clinician inspects a patient’s ROCF drawing and quantifies deviations from the original figure. This manual procedure is time-consuming, slow and scores vary depending on the clinician’s experience, motivation, and tiredness. Here, we leverage novel deep learning architectures to automatize the rating of memory deficits. For this, we collected more than 20k hand-drawn ROCF drawings from patients with various neurological and psychiatric disorders as well as healthy participants. Unbiased ground truth ROCF scores were obtained from crowdsourced human intelligence. This dataset was used to train and evaluate a multihead convolutional neural network. The model performs highly unbiased as it yielded predictions very close to the ground truth and the error was similarly distributed around zero. The neural network outperforms both online raters and clinicians. The scoring system can reliably identify and accurately score individual figure elements in previously unseen ROCF drawings, which facilitates explainability of the AI-scoring system. To ensure generalizability and clinical utility, the model performance was successfully replicated in a large independent prospective validation study that was pre-registered prior to data collection. Our AI-powered scoring system provides healthcare institutions worldwide with a digital tool to assess objectively, reliably, and time-efficiently the performance in the ROCF test from hand-drawn images.

    1. Neuroscience

    Brain Activity: Unifying networks of a rhythm

    Mohsen Alavash
    Insight

    Combining electrophysiological, anatomical and functional brain maps reveals networks of beta neural activity that align with dopamine uptake.